SLC5A2 and type 2 diabetes mellitus: The Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58 (DECLARE-TIMI58) trial demonstrated heterogeneous MACE outcomes and attenuated renoprotective outcomes in patients with type 2 diabetes disease duration greater than 20 years who were randomised to receive an SGLT2 inhibitor [25].